Profile

Cover photo
Paul Chambers
Lives in United States
1,346 followers|1,317,823 views
AboutPostsPhotosYouTube+1'sReviews

Stream

Pinned

Paul Chambers

Shared publicly  - 
 
FYI: Circle me and when I circle you back you will see my freshest and most latest posts. I rarely post to public to avoid trolls.
1
Add a comment...

Paul Chambers

Shared publicly  - 
 
Depression and Parkinsonism goes hand and hand. Disgusted at so called media and news outlets, esp the ones with health sections, having stories that reports depression as a surprise or new development. 
5
Tom McGill's profile photo
 
You noticed too?  Rather awful.
Add a comment...

Paul Chambers

Shared publicly  - 
 
My Robin Williams Death post from a guy fighting to live
I've been on a feeding tube for two 1/2 years, have a cardiac implant and a spinal pump for medication delivery.

Robin Williams movies are my "go to" movies when I am feeling Down , esp about my health. I was watching Mork and Mindy on Hulu when my tablet chimed with the breaking news of his suicide. I never met him but feel he was my friend. That is just how good he was at what he did.

Having a progressive, fatal illness, esp young , makes you dive into subject matters best left to old age. I've been lucky I have a progressive disease and have out lived the normal range with it. You evolve into accepting, even though you are fighting it, death.

I don't have a disease that can eliminate the fatalness of it by losing weight, stopping smoking, eating less little Debbie's for my sugar, etc. My life won't be extended by not drinking and driving or by avoid ing drugs. Nothing can be done. You treat the issues as the come up and wait for the undertaker. No cure.. Every now and again a patient lives out the far end of the prognosis. For this I am in overtime.

In many aspects depression is like that too. Its not the blues or pity party. Sometimes, as I presume in Robin Williams life, the meds and treatment just stop working and in a split second or hour, fatality hits. At some point that split second will hit me.

Having dealt with life and death, I can view it a little different than most. No offense but I am the one with a feeding tube and technically been on advanced life support for more than two years. I can't lay flat even because my muscles won't respirate my lungs.

With that in mind, In Robin Williams fashion and humor, I will not say he killed himself. Instead, I will say He cut in line!

#robinwilliams
7
John Poteet's profile photo
 
I feel ya brother. 
Add a comment...

Paul Chambers

Shared publicly  - 
 
Coroner leaves body parts at scene of Death, told family to bury parts under a tree 

"Dr. Varnau severely damaged her chances of not being suspended by admitting that she told Ms. Elfers to bury the extra skull fragments under a tree. Dr. Varnau said that it’s a common thing to say as an OB/GYN doctor."

Other issues, transporting bodies in old pickup truck, in a car on a tow truck, storing dead bodies in the garage at her house, giving weapons and guns to potential murder suspects.

http://newsdemocrat.com/news/home_top/4545934/Coroner-case-goes-to-court
GEORGETOWN — A decision on the motion to suspend the Brown County Coroner pending the next hearing will be made by the end of the week, ac...
1
Add a comment...

Paul Chambers

Shared publicly  - 
 
I have two posts. Post "A" which is this and post "b". If you see post a and not post b, please let me know. I am doing circle maintenance.
1
Doyin Oyelaran's profile photoChris Harpner (CSharpner)'s profile photoKienan Vella's profile photo
3 comments
 
I've got both
Add a comment...

Paul Chambers

Shared publicly  - 
 
If #hobbylobby was really damned to hell over birth control to their employees, then why is thine business based on cheap China imports, you know, China, who has the ultimate birth control programs? Seems like more hypocrisy.
2
2
Jason S's profile photoRyk Good's profile photo
Add a comment...
Have him in circles
1,346 people
Stephen Perciballi's profile photo
Javaid Iqbal's profile photo
Paul Davies C's profile photo
Premium Imprints LLC's profile photo
Venkatesh Amirthalingam's profile photo
BorderRegionTV's profile photo
Mark R Stern's profile photo
Cris Hdj's profile photo
Iris Carden's profile photo

Paul Chambers

Shared publicly  - 
 
New FDA advisory regarding GBCA contrast agents in MRI's

New concerns for persons who have had four or more contrast MRI's.

After being administered, GBCAs are mostly eliminated from the body through the kidneys. However, trace amounts of gadolinium may stay in the body long-term. Recent studies conducted in people and animals have confirmed that gadolinium can remain in the brain, even in individuals with normal kidney function. Available information does not identify any adverse health effects.

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm456012.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
Health care professionals should consider limiting GBCA use to clinical circumstances in which the additional information provided by the contrast is necessary.
2
1
Paul Chambers's profile photoTom McGill's profile photoDavid Stein's profile photoDarin Allan's profile photo
12 comments
 
+Tom McGill either way, I've had several of each in the past two years.
Add a comment...

Paul Chambers

Latest MS News  - 
 
Skyrocketing MS Drug Costs in US 'Alarming'

A new study documents what researchers are calling an "alarming" rise in costs for multiple sclerosis (MS) disease-modifying therapies (DMTs) in the United States and not just for newer oral medications.

"While we would expect that legitimate advances, such as the development of oral DMTs, might garner higher prices, the escalation in costs for first-generation agents that have been available for up to two decades is puzzling," Daniel M. Hartung, PharmD, MPH, and colleagues from Oregon Health & Science University, Portland, note in their article in the May 26 issue of Neurology.

"The issue of cost for DMT for MS is an increasing concern," Dr Hartung commented in a Neurology podcast.

"A flourishing pharmaceutical industry provides invaluable benefit to society by developing new drugs to combat disease and alleviate suffering," the authors write. "The success of the pharmaceutical industry in bringing new therapies to market for the treatment of MS has improved the care of people with MS.

"However, the unbridled rise in the cost of MS drugs has resulted in large profit margins and the creation of an industry 'too big to fail,'" they conclude. "It is time for neurologists to begin a national conversation about unsustainable and suffocating drug costs for people with MS — otherwise we are failing our patients and society."

Access Problems

The researchers examined about 20 years (1993–2013) of drug pricing data for nine MS DMTs, starting with the initially approved injectable medications — interferon β-1b (Betaseron, Bayer), interferon β-1a IM (Avonex, Biogen), and glatiramer acetate (Copaxone, Teva Pharm) — up to the newest oral agents — fingolimod (Gilenya, Novartis), teriflunomide (Aubagio, Genzyme/Sanofi), and dimethyl fumarate (Tecfidera, Biogen).

Their analysis showed that the first-generation DMTs, originally costing $8000 to $11,000 annually, now cost roughly $60,000 per year. The price of these older agents has increased annually at rates five to seven times higher than general prescription drug inflation. The newer oral agents commonly hit the US market with a cost 25% to 60% higher than existing MS DMTs, the authors note.

"The rising cost of many of the agents, in particular the three oldest agents — Betaseron, Avonex, and Copaxone — has not been uniform and seems actually from our data to be accelerated by approval of some of the newer agents," Dr Hartung commented.

He noted that significant increases in the cost trajectory of the first-generation DMTs occurred following the US Food and Drug Administration (FDA) approval in 2002 of interferon β-1a SC (Rebif, Merck Serono) and natalizumab (Tysabri, Biogen; reintroduced in 2006) and remained high following introduction of fingolimod in 2010.

The cost of MS DMTs in the United States is currently two to three times higher than in other similar countries, including the United Kingdom, Australia, and Canada, the authors note. The increases over the years in MS DMTs are not consistent with other prescription drug inflation metrics, Dr Hartung noted. In fact, they are "way out of line" in relation to a variety of comparisons.

The high cost of these agents is causing "real substantial access problems for patients," Dr Hartung warned. "Many insurance companies have been forced to use increasingly restrictive policies to manage cost and make people fail certain therapies before perhaps getting one of the oral agents," he noted.

"Because therapy for MS is very individualized, these types of regimented policies are not ideal for this disease state. While neurologists may become angry or frustrated over these increasing barriers that are put in place by payers, it is important to realize that the core reason for these restrictions is this escalation in cost, which is caused by the pharmaceutical industry," Dr Hartung said.

Holly Campbell, communications director, Pharmaceutical Manufacturers Association, told Medscape Medical News this study "doesn't tell the whole story because it does not take into account the competitive biopharmaceutical market that exists in the US, which helps to control costs while encouraging the development of new therapies for multiple sclerosis.

"The report only looks at the list prices of medicines, which typically do not reflect the substantial discounts negotiated by insurers," she said. "Similar price negotiation also happens in the successful Medicare Part D program. Focusing on list prices for a small group of medicines results in a misleading impression about the overall spending on medicines trend, which is just 10% of total US health care spending."

"Defies Common Sense"

In the Neurology podcast, David E. Jones, MD, from the MS Clinic at the University of Virginia, Charlottesville, who wasn't involved in the study, noted that MS neurologists have been "concerned for years" about the rapidly increasing price of MS DMTs, "but it seems like little has been written or done about this." Dr Hartung and colleagues have tackled "an area that needed to be addressed," Dr Jones said.

The coauthors of an editorial in Neurology, T. Jock Murray, MD, and Murray G. Brown, PhD, from Dalhousie University, Nova Scotia, Canada, say what has happened with MS DMT costs in the United States "defies common sense, logic, and the expected rules of the marketplace." After approval of the newer oral agents, the "skyward escalation" in prices of all DMTs was not expected.

"These price increases, and emerging evidence that long-term outcomes are less than anticipated, undermine the cost-effectiveness of MS DMTs. These counterintuitive increases suggest the possibility of collusion among the manufacturers, but the authors say they do not have evidence," Dr Murray and Dr Brown note.

Dr Hartung and colleagues say there is "an urgent need" for clinicians, payers, and manufacturers in the United States to confront the "soaring" costs of DMTs.

Dr Hartung encourages neurologists through their professional organizations, including the American Academy of Neurology and the National MS Society, to "take a strong stand against the aggressive pricing increases that have occurred."

"When you look at other fields, such as oncology and hepatitis C, there is a lot of public outcry against the pricing practices and it has allowed some concessions in terms of the prices for some of the new hepatitis C drugs as well as some cancer agents," he noted. "The publicity and acknowledgment of this pricing phenomenon I think will go a long way to hopefully stabilizing the cost of some of these agents."

Dr Murray and Dr Brown agree action is needed. "The ethics of medical professionalism requires physicians to be advocates for their patients. Hartung et al. ask that neurologists become concerned and initiate a national conversation on this issue, which is relevant also to conditions other than MS, such as cancer and hepatitis C. We cannot just be concerned — our professional ethic requires us to act," they write.

MS Society "Deeply" Concerned

Reached for comment on the study, Timothy Coetzee, PhD, chief advocacy, services and research officer at the National MS Society, said, "Access to affordable, high-quality healthcare is essential for people with multiple sclerosis to live their best lives. The evidence tells us that early and ongoing treatment with an MS disease-modifying therapy is vitally important to controlling disease activity, delaying the accumulation of disability, and protecting the quality of life for people with multiple sclerosis. However, today's healthcare reality is that the high cost of these important therapies prevents full access to them.

"The Society is deeply concerned by the rising costs of the MS therapies and the negative impact that this has on individuals being able to access these treatments," Dr Coetzee told Medscape Medical News. "People with MS must have full access to affordable health care. The Society is committed to bringing together all the stakeholders in this issue to find viable solutions to lower the overall costs of MS care and expand the medication formularies available to people with MS."

"While work proceeds on the public policy side, the Society focuses on helping to ensure that people with MS have access to the therapies they need by assisting them to tap into available options and assistance programs. Our work is grounded in our Access to High Quality MS Healthcare Principles, which are the foundation for all of our actions," Dr Coetzee said.

The study had no targeted funding. Dr Hartung, Dr. Murray, and Dr Brown have disclosed no relevant financial relationships. A full list of author disclosures is available at Neurology.org.

By
Megan Brooks

Neurology. 2015;84:2105-2106, 2185-2192. Abstract Editorial

 
Medscape Medical News © 2015  WebMD, LLC
Send comments and news tips to news@medscape.net.

Cite this article: Skyrocketing MS Drug Costs in US 'Alarming'. Medscape. May 27, 2015.
12
3
Grant Davison's profile photoKimiko Phoenix (Papa Dragon's kitten)'s profile photoTreasa Rice's profile photoGinny Otte's profile photo
5 comments
 
At least someone is profiting off us... pretty pathetic! Hope they choke on their caviar... LOL
Add a comment...

Paul Chambers

Shared publicly  - 
 
Bankruptcy Count sells Aereo's customer list to TIVo. Sales email ensues. Great, next Radio Shack +Senator Elizabeth Warren+Senator Bernie Sanders

TiVo OTA is not the same as #aereo. If you live in a OTA dead zone like me all you get is a $150 cancelation fee for months 1-12 and $75 for months 13-24.


1
Add a comment...

Paul Chambers

Shared publicly  - 
 
you who,yeah you while adjusting my circles I have sort of messed a few things up and some of you are gone. If you see a post called post a and then don't see post b, please let me know. I am going to manually try to find you but it could take awhile. 
1
Add a comment...

Paul Chambers

Shared publicly  - 
 
Attention Diabetics Abbott Diabetes Care has identified that certain meters have the potential to produce erroneously low blood glucose results when used in conjunction with certain Free Style test strips. This issue occurs with FreeStyle, FreeStyle Flash Blood Glucose meters and the FreeStyle blood glucose meter built into the OmniPod Insulin Management System. Affected meters and test strips have been identified by Abbott and customer notification letters with specific instructions for each product have been issued.  For more information, please see http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm392981.htm
3
4
Bill Ries-Knight (Steelhoof)'s profile photoChris Harpner (CSharpner)'s profile photoDarin Allan's profile photoJustin H's profile photo
 
Thank you Paul bad numbers are just as dangerous as no numbers sometimes worse
Add a comment...
People
Have him in circles
1,346 people
Stephen Perciballi's profile photo
Javaid Iqbal's profile photo
Paul Davies C's profile photo
Premium Imprints LLC's profile photo
Venkatesh Amirthalingam's profile photo
BorderRegionTV's profile photo
Mark R Stern's profile photo
Cris Hdj's profile photo
Iris Carden's profile photo
Collections Paul is following
Places
Map of the places this user has livedMap of the places this user has livedMap of the places this user has lived
Currently
United States
Links
Story
Tagline
Hope is on the horizon if you don't look back.
Bragging rights
Disability Advocate, Feeding Tube survivor, heck of a nice guy.
Work
Occupation
...Working full-time @ living
Skills
PHP, Linux, Enteral Feeding, Baclofen Pump,
Basic Information
Gender
Male
Paul Chambers's +1's are the things they like, agree with, or want to recommend.
PrimeTime for Google TV
market.android.com

PrimeTime for Google TV works for you so you never miss out. Bringing together everything on your cable/satellite TV, Netflix, YouTube, and

Android L Keyboard
market.android.com

The keyboard from the Android L Developer Preview, modified to run as a standalone app by Chrisch1974 and I. Free, no ads, no bloat. No root

Post Office Closed. New zip Code for this area is 45118 and serves out of Fayetteville, Oh Post office.
Public - 4 months ago
reviewed 4 months ago
1 review
Map
Map
Map